RE:RE:RE:RE:RE:RE:RE:Sad newsFor this phase of the trial not much. It's about dosage and then safety and efficacy. But sounds like he likely never got up to a therapeutic dose level. Someone earlier on pointed out the difficulty of all-comer trials for a fourth line treatment where nothing has ever helped the patient. In those conditions, one has to expect numerous issues such as this can ultimately occur. As we've seen with most of these trials, just adding 2-3 months is a massive improvement, but the probability for refractory and spreading tumors is usually not good and this is what happens. It's to be expected.
It will be interesting to see if there is an ultimate positive outcome in Phase 2 and 3, if the oncology community would want to see it used much earlier in the process. Will all come down to sortilin expression and efficacy and response rates.
Bucknelly21 wrote: What does this mean for th1902